Navigation Links
Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
Date:9/28/2007

e on what we believe is most critical to our future success -- building and advancing our pipeline."

Idenix currently has a non-nucleoside reverse transcriptase inhibitor (NNRTI), IDX899, for the treatment of HIV-1 that is being evaluated in phase I/II clinical testing. The company also has a comprehensive HCV discovery effort, comprised of a next-generation nucleoside polymerase inhibitor program, including IDX102 and IDX184, which are currently being evaluated in advanced preclinical testing, and HCV non-nucleoside polymerase inhibitor and HCV protease inhibitor programs.

As a result of this restructuring, Idenix will incur between $5 million and $10 million in charges, primarily associated with one-time employee severance benefits and the write-off of certain assets. The company continues to expect to end 2007 with between $100 million and $110 million of cash, cash equivalents and marketable securities. Idenix estimates that this restructuring will result in savings of $40 million to $45 million on an annual basis.

"We have taken the steps necessary to streamline our organization and significantly reduce our expenses, while continuing to maintain the strength of our balance sheet," said Ronald Renaud, Jr., chief financial officer of Idenix. "We believe that we are now well-positioned to fund the advancement of our HIV and HCV discovery and development programs through 2009."

About Idenix/Novartis Collaboration

Idenix and Novartis Pharma AG established a collaboration in May 2003, at which point Novartis became a majority shareholder in Idenix. Currently, Novartis owns 56% of Idenix and has first right of refusal to Idenix's pipeline.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caus
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Front-face detection for high-concentrate, opaque or solid sample
4. Concentrated solar energy project wins Innovation Days prizes
5. Wisconsin stands at the center of scientific efforts to avert flu epidemics
6. Thompsons HHS legacy will include efforts to combat disease in Africa
7. Efforts to avoid friendly fire spawned ancestor of todays RFID
8. Manufacturing group says efforts led to big improvements
9. Madison grid computing efforts attack big research questions
10. Californian stem-cell efforts get new rules, attract lawsuits
11. Tech Council passes E-Learning efforts for Northern Wisconsin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... the key challenges in the development of quantum technologies ... In a paper published today (28 October) in ... how to make a new type of flexibly designed ... as high-precision sensors and specialised superfast computers, often depend ... methods for trapping these tiny particles are hugely problematic ...
(Date:10/27/2014)... and TORONTO , ... ( www.generex.com ) (OTCQB: GNBT) today announced two ... response triggered by its novel proprietary cancer immunotherapeutic ... in breast cancer patients. The AE37 cancer vaccine ... Antigen Express, Inc. ( www.antigenexpress.com ). The presentations ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 The ... Management, Intelligent Traffic Management, Communication, Monitoring), and by ... Forecast to 2019” segments the global market into ... revenues. It also identifies the drivers and restraints ... and challenges. , Browse 75 market tables and ...
(Date:10/26/2014)... report "Protective Coatings Market by Resin Type, by Technology ... 2019", defines and segments the global protective coatings market ... generated. The protective coatings consumption is projected to grow ... 2019, at a CAGR of 9.52% during the same ... figures spread through 219 slides and in-depth TOC on ...
Breaking Biology Technology:Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4
... invention from Tel Aviv University a network of tiny ... foil even the most determined intruder. Scattered outdoors on ... of a bank, the dewdrops are a completely new and ... , Prof. Yoram Shapira and his Tel Aviv University Faculty ...
... (R) (lacosamide) C-V, a new antiepileptic drug (AED), ... week of June 2009. Vimpat was approved by ... the use as an add-on therapy for the treatment ... with epilepsy.(Photo: http://www.newscom.com/cgi-bin/prnh/20090526/NY22555 )Vimpat approval is ...
... old man with inoperable lung cancer is able to ... Surgeons told Donald Bickford, 71, that due to ... not an option for removing his lung tumor. To ... Wentworth-Douglass Hospital here, prescribed a type of non-invasive radiosurgery ...
Cached Biology Technology:Intruder alert: Tel Aviv University's 'Smart Dew' will find you! 2Vimpat(R) (lacosamide) C-V, a New Antiepileptic Drug (AED), To Be Available in U.S. Pharmacies 2Vimpat(R) (lacosamide) C-V, a New Antiepileptic Drug (AED), To Be Available in U.S. Pharmacies 3Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology 2Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology 3
(Date:10/29/2014)... but they also need protection from its harmful rays, just ... in plants that shields them from sun damage. Now, in ... Society , one team reports on the mechanics of how ... at Purdue University note that the harsh ultraviolet radiation plants ... DNA and, as a result, hinder plant growth. Biochemical ...
(Date:10/29/2014)... German . ... Schlögelhofer at the Max F. Perutz Laboratories (MFPL) of ... Vienna dived into the process of meiosis in specific ... inversion of the standard meiotic phases. The researchers describe ... Communications . , Meiosis is the two-step series of ...
(Date:10/29/2014)... October 29, 2014 – Ghrelin is a hormone released ... intake. Alcohol is commonly viewed as a psychoactive substance ... a highly caloric food. , This knowledge, combined ... hypothesis that ghrelin has the potential to stimulate alcohol ... this in humans and found that, as they had ...
Breaking Biology News(10 mins):Meiotic cell division 'the other way round' 2Ghrelin stimulates an appetite for drinking alcohol 2
... analysis indicates that birds don,t fly alone when migrating at ... journeys, flying in tandem even when they are 200 meters ... University of Illinois and the Illinois Natural History Survey, appears ... is the first to confirm with statistical data what many ...
... numbers of cycles of preimplantation genetic diagnosis or screening ... in 2004 (the most recent year for which data ... a growing number of genetically related conditions, but what ... condition are available for transfer and the parents request ...
... the journal Plant Physiology provides a comprehensive ... the rapidly growing Rosaceae scientific community. ... that comprises more than 3,000 species, including strawberry, apple, ... high-value nutritional foods and they are also the source ...
Cached Biology News:Birds migrate together at night in dispersed flocks, new study indicates 2Birds migrate together at night in dispersed flocks, new study indicates 3Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 2Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 3Review article provides tools for the Rosaceae genomics community 2
...
Request Info...
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Biology Products: